Outcome MeasureOther

PGIC

Patient Global Impression of Change

3 Papers in Blossom

Clinical Thresholds

17
Very much improved
Score 1–1
Much improved
Score 2–2
Minimally improved
Score 3–3
No change
Score 4–4
Minimally worse
Score 5–5
Much worse
Score 6–6
Very much worse
Score 7–7

Outcome Data Across Studies

Reported results for PGIC across 2 studies with quantitative data.

Outcome data across 5 study arm–timepoint observations
SD
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression
2016Secondary
Ketamine 2x/week(experimental)29182.0——
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression
2016Secondary
Placebo 2x/week(inactive)29164.0——
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression
2016Secondary
Ketamine 3x/week(experimental)29173.0——
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression
2016Secondary
Placebo 3x/week(inactive)29164.0——
Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, proof-of-concept clinical trial
2025Secondary
Oral Psilocybin + Therapy(experimental)6452.0——

Papers Using PGIC

Paywallindividual

A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression

This 12‑week, open‑label Phase IIa trial of a single 10 mg intranasal dose of 5‑MeO-DMT (BPL‑003) in patients (n=12) with treatment‑resistant major depressive disorder, found that the drug was generally well tolerated with mostly mild–moderate adverse events and rapid discharge readiness (median ~98 minutes). A rapid and sustained mean MADRS reduction of 12–13 points was observed from Day 2 through Day 85, with most participants meeting response criteria and several achieving remission, supporting further evaluation in larger controlled trials.

Published
Journal
Journal of Psychopharmacology
Authors
Roberts, C., Seynaeve, M., Ermakova, A. O., Dunbar, F., Wells, H., Puri, A., Bird, C., Rucker, J. J.
Open Accessindividual

Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, proof-of-concept clinical trial

In an open-label proof-of-concept trial (N=5), psilocybin-assisted therapy was well tolerated in adults with fibromyalgia, producing only transient elevations in blood pressure/heart rate and non-serious post-dose headaches. Participants showed clinically meaningful improvements in pain severity, pain interference and sleep disturbance one month after treatment, supporting progression to larger randomised controlled trials.

Published
Journal
Frontiers in Pain Research
Authors
Aday, J. S., Mcafee, J., Conroy, D. A., Hosanagar, A., Tarnal, V., Weston, C., Scott, K., Horowitz, D., Harte, S. E., Pouyan, N., Glynos, N. G., Baker, A. K., Guss, J., Davis, A. K., Burgess, H. J., Mashour, G. A., Clauw, D. J., Boehnke, K. F.
Open Accessindividual

A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression

This multicenter, double-blind, randomised, placebo-controlled study (n=67) investigated the antidepressant effects of ketamine (35mg/70kg) in relation to the dose frequency administered to patients with depression (TRD). Results indicated that both a twice-weekly and thrice-weekly administration regimen maintained antidepressant efficacy over 15 days.

Published
Journal
American Journal of Psychiatry
Authors
Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., Kurian, B., Winokur, A., Fava, M., Manji, H., Drevets, W. C., Nueten, V.

Quick Facts

Full Name
Patient Global Impression of Change
Domain
Other
Papers Indexed
3
Score Range
1–7
Interpretation
Lower = better
Unit
points
All Measures